Similar articles for PMID: 30549066

Year	Number of Results
2006	1
2012	3
2013	6
2014	3
2015	7
2016	17
2017	30
2018	32
2019	33
2020	34
2021	33
2022	50
2023	15
2024	0

1

68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.

Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, Maucherat B, Baumgartner P, Fleury V, Colombié M, Thierry-Morel A, Kraeber-Bodéré F, Campion L, Rousseau C. Barbaud M, et al. Prostate. 2019 Apr;79(5):454-461. doi: 10.1002/pros.23751. Epub 2018 Dec 14. Prostate. 2019. PMID: 30549066

2

Preliminary results of a ⁶⁸ Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.

Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F. Rousseau C, et al. Prostate. 2019 Sep;79(13):1514-1522. doi: 10.1002/pros.23869. Epub 2019 Aug 17. Prostate. 2019. PMID: 31421657 Clinical Trial.

3

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

4

Multiphasic ⁶⁸Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients.

Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, Langsteger W. Beheshti M, et al. J Nucl Med. 2020 Oct;61(10):1484-1490. doi: 10.2967/jnumed.119.238071. Epub 2020 Feb 14. J Nucl Med. 2020. PMID: 32060214 Free article.

5

Detection Efficacy of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.

Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M. Einspieler I, et al. J Nucl Med. 2017 Jul;58(7):1081-1087. doi: 10.2967/jnumed.116.184457. Epub 2017 Feb 16. J Nucl Med. 2017. PMID: 28209912 Free article.

6

⁶⁸Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. von Eyben FE, et al. Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15. Eur Urol Focus. 2018. PMID: 28753806 Free article.

7

A Multicenter Prospective Clinical Trial of ⁶⁸Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.

McCarthy M, Francis R, Tang C, Watts J, Campbell A. McCarthy M, et al. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):801-808. doi: 10.1016/j.ijrobp.2019.03.014. Epub 2019 Mar 16. Int J Radiat Oncol Biol Phys. 2019. PMID: 30890448 Clinical Trial.

8

Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.

De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F. De Bari B, et al. Radiol Med. 2018 Sep;123(9):719-725. doi: 10.1007/s11547-018-0890-7. Epub 2018 Apr 23. Radiol Med. 2018. PMID: 29687208

9

⁶⁸Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.

Caroli P, Sandler I, Matteucci F, De Giorgi U, Uccelli L, Celli M, Foca F, Barone D, Romeo A, Sarnelli A, Paganelli G. Caroli P, et al. Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2035-2044. doi: 10.1007/s00259-018-4067-3. Epub 2018 Jun 19. Eur J Nucl Med Mol Imaging. 2018. PMID: 29922948

10

[PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of ⁶⁸Ga-PSMA-11 when ¹⁸F-fluorocholine is non-contributive].

Gauthé M, Belissant O, Girard A, Zhang Yin J, Ohnona J, Cottereau AS, Nataf V, Balogova S, Pontvert D, Lebret T, Guillonneau B, Cussenot O, Talbot JN. Gauthé M, et al. Prog Urol. 2017 Jun-Jul;27(8-9):474-481. doi: 10.1016/j.purol.2017.04.004. Epub 2017 May 30. Prog Urol. 2017. PMID: 28576423 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

215 results

Results by year